Strong Merck stock trades near a 52-week high as cancer vaccine data boost Keytruda

Merck & Co., Inc. (ISIN US58933Y1055) stock has been trading close to a fresh 52-week high in late August 2026, supported by new Phase 3 data for a personalized mRNA cancer vaccine that builds on the company’s blockbuster immunotherapy Keytruda and keeps investor attention on its oncology pipeline. As of August 23, 2026, recent market commentary cited Merck shares opening at $152.43, close to a reported 52-week high of $154.49, underscoring strong recent performance ahead of the next earnings update.

New melanoma vaccine data support the Keytruda franchise

Recent reporting on August 24, 2026 highlighted that a Phase 3 adjuvant trial in high-risk melanoma combining an investigational personalized mRNA vaccine, intismeran autogene (also referred to as V940 or mRNA-4157), with Merck’s immunotherapy Keytruda achieved statistically significant improvements in recurrence-free survival and distant metastasis-free survival compared with Keytruda alone. One detailed article on the trial results noted that this is the first time a personalized neoantigen therapy and an mRNA-based cancer treatment have delivered positive Phase 3 data, marking a milestone for the broader cancer vaccine field.

Additional coverage on August 24, 2026 reiterated that, in this large melanoma trial, patients receiving the personalized vaccine plus Keytruda experienced significantly lower rates of cancer recurrence than those treated with Keytruda alone, again emphasizing improvements in both recurrence-free survival and distant metastasis-free survival as key endpoints. This reporting stressed that detailed study findings are expected to be presented at an upcoming scientific meeting, which could provide more granular data on benefit in different patient subgroups.

Chinese-language financial coverage from August 24, 2026 pointed out that Merck announced on August 19, 2026 that the melanoma Phase 3 trial of intismeran combined with Keytruda had met its primary and key secondary endpoints, and highlighted that capital markets reacted with strong moves in the partners’ share prices at the time of the announcement. The same article recalled earlier data showing that, with Keytruda monotherapy, four-year recurrence-free survival in high-risk melanoma reached 71.3 percent, implying that there was still room to reduce the roughly 29 percent of patients who experienced recurrence or death, which frames the rationale for pairing Keytruda with a personalized vaccine.

Keytruda economics and emerging biosimilar race

South Korean and Korean-language business media on August 24, 2026 drew attention to the economic scale of Keytruda as a driver of Merck’s valuation, stating that last year Keytruda generated global sales of $31.7 billion, or about 44 trillion won, making it the world’s top-selling drug by revenue. One such article framed Keytruda as the leading immune-oncology agent, with approved indications spanning non-small cell lung cancer, melanoma, gastric cancer, head and neck cancer, and several other tumor types.

Coverage from another Korean outlet on August 24, 2026 highlighted that Keytruda’s substance patent is scheduled to expire in Korea in 2028, in the United States around late 2029, and in Europe in early 2031, outlining a staggered timeline for when biosimilar competition can fully enter major markets. That article added that Celltrion had filed for approval of a Keytruda biosimilar called CT-P51 with Korea’s drug regulator on August 24, 2026, joining other biosimilar developers preparing to target the same indication set once patents lapse.

An English-language story on August 24, 2026 similarly reported that Celltrion applied to the Korean regulator for approval of CT-P51, described as a biosimilar version of Merck’s blockbuster cancer drug Keytruda, thereby entering a domestic race among Korean companies to capture market share in the post-patent era. This coverage reinforced that biosimilar competition is not only a long-term threat to Keytruda’s pricing power but also a sign of how central the drug has become in oncology treatment algorithms.

Another Korean market-focused article on August 24, 2026 discussed the implications of the successful cancer vaccine trial for Keytruda’s subcutaneous (SC) formulation, noting that the strategic value of a SC version of Keytruda is increasing as cancer vaccines become more prominent. The same analysis indicated that, in a high-risk non-small cell lung cancer Phase 3 trial started in May, Keytruda SC was chosen as the combination partner for the personalized vaccine, and reported that the SC conversion rate reached 10.6 percent by July, with monthly sales rising from $23.10 million in January to $201.60 million in July on a wholesale acquisition cost basis, signaling rapid uptake of the new formulation.

Recent stock performance and market metrics

A same-day market-data overview on August 24, 2026 noted that Merck shares recently surged to a 52-week high of $154.49, extending a run of gains over two consecutive weeks, and tying that move to investor enthusiasm for the melanoma vaccine data and Merck’s broader oncology pipeline. The article described MRK stock as having jumped to that 52-week high level on August 22, 2026, setting a new price reference point that market participants now watch in relation to subsequent trading sessions.

In separate coverage dated August 23, 2026, a portfolio update piece focusing on institutional activity remarked that shares of Merck opened at $152.43 during that recent trading session and characterized the consensus rating on the stock as Moderate Buy, with an average price target of $144.10, albeit with some analysts flagging valuation and execution risks and paying attention to the 2028 patent expiration for Keytruda in key markets. That institutional report also stated that Merck shares were trading up 2.3 percent at the time, aligning with the narrative of a stock that has experienced a notable short-term rally, helped by the positive oncology news flow.

Another institutional trading update published on August 24, 2026 mentioned that Merck shares opened at $152.43 in the latest session and reiterated that the stock was trading down marginally by 0.1 percent at the time of that note, illustrating how the price is fluctuating in a relatively tight band close to the recent 52-week high. This separate piece underscores that, despite modest day-to-day moves, Merck remains valued near the higher end of its one-year trading range, and gives investors concrete reference points for price and institutional activity as of late August 2026.

Representative product Keytruda underpins Merck’s growth story

Keytruda, Merck’s flagship immune checkpoint inhibitor targeting PD-1, is central to the company’s growth profile and to the oncology-focused investor narrative. As described in the August 24, 2026 Korean business coverage, Keytruda is approved for a wide range of cancers, including non-small cell lung cancer, melanoma, gastric cancer, head and neck tumors, and other malignancies, and held the position of the top-selling drug globally last year with $31.7 billion in revenue. In high-risk melanoma, previous data showed that adjuvant treatment with Keytruda improved four-year recurrence-free survival to 71.3 percent, yet left a substantial minority of patients still facing recurrence or death, which is precisely the clinical problem that the new personalized mRNA vaccine is intended to address.

Keytruda’s mechanism of action involves blocking the PD-1 pathway to release the brakes on T cells, enabling them to recognize and attack residual cancer cells throughout the body. The personalized vaccine intismeran complements this approach by encoding patient-specific neoantigens, training the immune system more precisely against tumor-associated targets. Together, the combination has now demonstrated improvements in both recurrence-free survival and distant metastasis-free survival in a Phase 3 setting, according to the late-stage melanoma trial results reported in multiple outlets on August 24, 2026. For Merck, these data support a case for sustained oncology revenue from Keytruda and its combination strategies even as the company prepares for eventual patent expirations and competition from biosimilars like CT-P51.

Merck stock valuation context as of late August 2026

From an equity-market perspective, Merck stock’s move to a 52-week high of $154.49 in August 2026, followed by trading around $152.43 in subsequent sessions, reflects a balance between optimism about the oncology pipeline and caution regarding long-term patent and biosimilar dynamics. The cited Moderate Buy consensus and $144.10 average price target suggest that, while analysts broadly expect further value creation, the stock’s recent price level sits above the average target, which can prompt debates about whether short-term enthusiasm has run ahead of fundamentals.

For retail investors, the key numerical comparison highlighted in recent articles is the gap between the 52-week high of $154.49 and the recent opening price around $152.43, indicating that Merck shares are trading only a few dollars below their one-year peak after a two-week run of gains. At the same time, Keytruda’s last-year global sales of $31.7 billion and the patent-expiration schedule through 2028 in Korea and 2029 to 2031 in the United States and Europe frame expectations that Merck will need to continue delivering strong clinical and commercial data from its oncology portfolio, including cancer vaccines and SC formulations, to justify valuation at the upper end of its historical range over the longer term.

Read more

For further details on Merck & Co. stock and company disclosures, investors can review the materials available at the company’s investor relations site. This hub provides primary documentation on earnings, pipeline updates, and regulatory filings that complement the market-data and media coverage summarized here.

Keytruda’s clinical role in melanoma

In clinical practice, Keytruda is widely used as adjuvant therapy in high-risk melanoma following surgical resection, with the intention of reducing the risk of recurrence. Reports cited in the August 24, 2026 coverage explained that Keytruda, by releasing immune-system brakes, enables T cells to become active again and circulate through the body to seek and destroy residual cancer cells. With Keytruda alone, patients saw four-year recurrence-free survival reach 71.3 percent, leaving roughly 29 percent of patients experiencing recurrence or death, a statistic that underscores the severity of the disease even with modern immunotherapy.

The personalized cancer vaccine intismeran is designed to augment this effect by targeting neoantigens specific to each patient’s tumor. In the Phase 3 melanoma trial, pairing intismeran with Keytruda led to statistically significant improvements in recurrence-free survival and distant metastasis-free survival versus Keytruda alone, providing evidence that personalized vaccination may meaningfully improve outcomes beyond what checkpoint inhibition can deliver by itself. For Merck, this product pairing offers an avenue to preserve and expand the clinical relevance of Keytruda while also participating in the emerging market for mRNA-based cancer vaccines.

Merck stock level as of the latest session

Based on the recent quote snapshots described in institutional trading updates and market commentary dated August 23 and August 24, 2026, Merck shares were opening at $152.43 in the latest sessions, with one report noting a 2.3 percent gain during a prior trading day and another indicating a modest 0.1 percent decline in a more recent session. These figures, together with the reported 52-week high of $154.49 reached on August 22, 2026, provide a numerical frame for evaluating Merck stock’s position as of late August 2026: the shares are trading close to their one-year peak, supported by strong oncology news but also monitored for valuation risks and the impact of future biosimilar entry.